BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36892593)

  • 41. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical Significance of Minimal Residual Disease in Risk Stratification and Prognosis of Childhood B-lineage Acute Lymphoblastic Leukemia].
    An FY; Zhang SH; Kong LJ; Liang Y; Xu JX; He HL; Chai YH; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):729-735. PubMed ID: 28641626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of Ph-Negative Acute Lymphoblastic Leukemia in Adolescents and Young Adults with an Affordable Outpatient Pediatric Regimen.
    Gómez-De León A; Varela-Constantino AL; Colunga-Pedraza PR; Sánchez-Arteaga A; García-Zárate V; Rodríguez-Zúñiga AC; Méndez-Ramírez N; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Tarín-Arzaga L; González-López EE; Jaime-Pérez JC; Gómez-Almaguer D
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):883-893. PubMed ID: 36057522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
    Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Linkage of cell division cycle 42 with clinical features, treatment response and survival in adult Philadelphia chromosome negative acute lymphoblastic leukemia.
    Chen Q; Zhu X; He D; Ding W
    Scand J Clin Lab Invest; 2024 May; 84(3):139-146. PubMed ID: 38662870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
    Ribera JM; Morgades M; Ciudad J; Montesinos P; Esteve J; Genescà E; Barba P; Ribera J; García-Cadenas I; Moreno MJ; Martínez-Carballeira D; Torrent A; Martínez-Sánchez P; Monsalvo S; Gil C; Tormo M; Artola MT; Cervera M; González-Campos J; Rodríguez C; Bermúdez A; Novo A; Soria B; Coll R; Amigo ML; López-Martínez A; Fernández-Martín R; Serrano J; Mercadal S; Cladera A; Giménez-Conca A; Peñarrubia MJ; Abella E; Vall-Llovera F; Hernández-Rivas JM; Garcia-Guiñon A; Bergua JM; de Rueda B; Sánchez-Sánchez MJ; Serrano A; Calbacho M; Alonso N; Méndez-Sánchez JÁ; García-Boyero R; Olivares M; Barrena S; Zamora L; Granada I; Lhermitte L; Feliu E; Orfao A
    Blood; 2021 Apr; 137(14):1879-1894. PubMed ID: 33150388
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia.
    Farkas T; Müller J; Erdelyi DJ; Csoka M; Kovacs GT
    Pathol Oncol Res; 2017 Oct; 23(4):889-897. PubMed ID: 28138921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.
    Eckert C; Groeneveld-Krentz S; Kirschner-Schwabe R; Hagedorn N; Chen-Santel C; Bader P; Borkhardt A; Cario G; Escherich G; Panzer-Grümayer R; Astrahantseff K; Eggert A; Sramkova L; Attarbaschi A; Bourquin JP; Peters C; Henze G; von Stackelberg A;
    J Clin Oncol; 2019 Dec; 37(36):3493-3506. PubMed ID: 31644328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.
    Ding Z; Han MZ; Chen SL; Ma QL; Wei JL; Pang AM; Zhang XY; Liang C; Yao JF; Cao YG; Feng SZ; Jiang EL
    Chin Med J (Engl); 2015 Aug; 128(15):2065-71. PubMed ID: 26228220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG-ALL-2015: A multicenter study.
    Zhang H; Wan Y; Wang H; Cai J; Yu J; Hu S; Fang Y; Gao J; Jiang H; Yang M; Liang C; Jin R; Tian X; Ju X; Hu Q; Jiang H; Li Z; Wang N; Sun L; Leung AWK; Wu X; Qian X; Qian M; Li CK; Yang J; Tang J; Zhu X; Shen S; Zhang L; Pui CH; Zhai X
    Cancer; 2023 Jun; 129(11):1691-1703. PubMed ID: 36943767
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
    Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
    Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Hara R; Onizuka M; Kikkawa E; Shiraiwa S; Harada K; Aoyama Y; Ogiya D; Toyosaki M; Suzuki R; Machida S; Ohmachi K; Ogawa Y; Kawada H; Matsushita H; Ando K
    Ann Hematol; 2021 Oct; 100(10):2479-2486. PubMed ID: 34247299
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia.
    Zheng Y; Pan L; Li J; Feng X; Li C; Zheng M; Mai H; Yang L; He Y; He X; Xu H; Wen H; Le S
    BMC Cancer; 2024 Jan; 24(1):46. PubMed ID: 38195455
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India.
    Mishra V; Jain S; Anand V; Malhotra P; Tejwani N; Kapoor G
    Pediatr Hematol Oncol; 2023; 40(6):517-528. PubMed ID: 36930957
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.
    Esteve J; Giebel S; Labopin M; Czerw T; Wu D; Volin L; Socié G; Yakoub-Agha I; Maertens J; Cornelissen JJ; Pigneux A; Shimoni A; Schwerdtfeger R; Labussière-Wallet H; Russell N; Schattenberg A; Chevallier P; Koza V; Foà R; Schmid C; Peric Z; Mohty M; Nagler A
    Leukemia; 2021 Aug; 35(8):2232-2242. PubMed ID: 33542481
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia.
    Nagafuji K; Miyamoto T; Eto T; Ogawa R; Okumura H; Takase K; Kawano N; Miyazaki Y; Fujisaki T; Wake A; Ohno Y; Kurokawa T; Kamimura T; Takamatsu Y; Yokota S; Akashi K
    Eur J Haematol; 2019 Sep; 103(3):164-171. PubMed ID: 31132205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
    Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
    Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Long-term results of multicenter study based on childhood acute lymphoblastic leukemia 2005 protocol].
    Cai JY; Wang NL; Jiang H; Shen SH; Xue HL; Chen J; Pan C; Gao YJ; Sun LR; Yuan XJ; Gu LJ; Tang JY
    Zhonghua Er Ke Za Zhi; 2018 Jul; 56(7):511-517. PubMed ID: 29996184
    [No Abstract]   [Full Text] [Related]  

  • 59. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
    Pratz KW; Jonas BA; Pullarkat V; Recher C; Schuh AC; Thirman MJ; Garcia JS; DiNardo CD; Vorobyev V; Fracchiolla NS; Yeh SP; Jang JH; Ozcan M; Yamamoto K; Illes A; Zhou Y; Dail M; Chyla B; Potluri J; Döhner H
    J Clin Oncol; 2022 Mar; 40(8):855-865. PubMed ID: 34910556
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.
    Schrappe M; Aricò M; Harbott J; Biondi A; Zimmermann M; Conter V; Reiter A; Valsecchi MG; Gadner H; Basso G; Bartram CR; Lampert F; Riehm H; Masera G
    Blood; 1998 Oct; 92(8):2730-41. PubMed ID: 9763557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.